Register Login

Rigel Pharmaceuticals Inc (RIGL)

(90% Positive) Rigel Pharmaceuticals Inc (RIGL) Announces Enrollment Update for year Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Jan. 29, 2026, 8:35 p.m.

    📋 Rigel Pharmaceuticals Inc (RIGL) - Clinical Trial Update

    Filing Date: 2026-01-12

    Accepted: 2026-01-12 08:15:09

    Event Type: Clinical Trial Update

    Event Details:

    Rigel Pharmaceuticals Inc (RIGL) Announces Clinical Trial Update Rigel Pharmaceuticals Inc (RIGL) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: year, income
    • Clinical Stage: Phase 2
    • Collaboration: RBC
    • Updated Timeline: 2026 Outlook•Preliminary fourth quarter 2025, the fourth quarter of 2025
      • anticipated in such forward looking statements as a result of these risks and uncertainties, which include, without limitation, the finalization and audit of Rigel’s fourth quarter and 2025

    🔬 Clinical Development Pipeline (Rigel Pharmaceuticals Inc):

    Product Type Development Stage Therapeutic Area Source
    Olutasidenib Investigational Agent Administration DRUG Phase PHASE1 Acute Myeloid Leukemia ClinicalTrials.gov
    Venetoclax DRUG Phase PHASE2 Targeted Therapy ClinicalTrials.gov
    Cytarabine DRUG Phase PHASE2 Targeted Therapy ClinicalTrials.gov
    Ruxolitinib DRUG Phase PHASE2 Targeted Therapy ClinicalTrials.gov
    Gilteritinib DRUG Phase PHASE2 Targeted Therapy ClinicalTrials.gov
    Cladribine (CLAD) DRUG Phase PHASE2 Targeted Therapy ClinicalTrials.gov
    Olutasidenib DRUG Phase PHASE2 Targeted Therapy ClinicalTrials.gov
    Azacitidine DRUG Phase PHASE2 Acute Myeloid Leukemia ClinicalTrials.gov
    Standard of care OTHER Phase PHASE1 Coronavirus ClinicalTrials.gov
    Fostamatinib DRUG Phase PHASE1 Coronavirus ClinicalTrials.gov
    R906289 Monosodium (R289 Na) DRUG Phase PHASE1 Low Risk Myelodysplastic Syndromes ClinicalTrials.gov
    Placebo DRUG Phase PHASE2 Acute Respiratory Distress Syndrome ClinicalTrials.gov
    Beclomethasone dipropionate DRUG Phase PHASE2 Rhinitis, Allergic, Seasonal ClinicalTrials.gov
    R926112 DRUG Phase PHASE2 Rhinitis, Allergic, Seasonal ClinicalTrials.gov
    R788 DRUG Phase PHASE2 Rheumatoid Arthritis ClinicalTrials.gov
    valaciclovir DRUG Phase PHASE2 Herpes Zoster ClinicalTrials.gov
    ARYS-01 (sorivudine) cream 3% or placebo cream DRUG Phase PHASE2 Herpes Zoster ClinicalTrials.gov
    Fostamatinib Disodium (R935788) DRUG Phase PHASE2 Systemic Lupus Erythematosus ClinicalTrials.gov
    Fostamatinib Disodium tablet 150 mg DRUG Phase PHASE2 IGA Nephropathy ClinicalTrials.gov
    Fostamatinib Disodium tablet 100 mg DRUG Phase PHASE2 IGA Nephropathy ClinicalTrials.gov
    R932333 DRUG Phase PHASE2 Lupus Erythematosus, Discoid ClinicalTrials.gov
    R348 Ophthalmic Solution, 1.0% DRUG Phase PHASE1 Keratoconjunctivitis Sicca ClinicalTrials.gov
    R348 Ophthalmic Solution, 0.5% DRUG Phase PHASE1 Keratoconjunctivitis Sicca ClinicalTrials.gov
    R348 Ophthalmic Solution, 0.2% DRUG Phase PHASE1 Keratoconjunctivitis Sicca ClinicalTrials.gov
    Placebo Ophthalmic Solution OTHER Phase PHASE2 Chronic Graft-versus-host Disease ClinicalTrials.gov
    Fostamatinib Disodium DRUG Phase PHASE2 T Cell Lymphoma ClinicalTrials.gov
    R940343 2mg DRUG Phase PHASE2 Asthma ClinicalTrials.gov
    R940343 1mg DRUG Phase PHASE2 Asthma ClinicalTrials.gov
    Fostamatinib Disodium / R935788 DRUG Phase PHASE2 Purpura, Thrombocytopenic, Idiopathic ClinicalTrials.gov
    Fostamatinib disodium 150 mg DRUG Preclinical Immune Thrombocytopenic Purpura ClinicalTrials.gov
    Fostamatinib disodium 100 mg DRUG Preclinical Immune Thrombocytopenic Purpura ClinicalTrials.gov
    Fostamatinib 100 mg DRUG Phase PHASE2 IGA Nephropathy ClinicalTrials.gov
    Fostamatinib 150 mg DRUG Phase PHASE2 IGA Nephropathy ClinicalTrials.gov
    Fostamatinib 150 mg bid DRUG Phase PHASE2 Warm Antibody Autoimmune Hemolytic Anemia ClinicalTrials.gov
    Decitabine/cedazuridine DRUG Phase PHASE1 Mutant IDH1 Inhibitor Olutasidenib ClinicalTrials.gov
    Decitabine DRUG Phase PHASE1 Mutant IDH1 Inhibitor Olutasidenib ClinicalTrials.gov
    Olutasidenib + TMZ DRUG Phase PHASE2 High Grade Glioma ClinicalTrials.gov
    Fostamatinib 200 mg bid and Paclitaxel DRUG Phase PHASE1 Ovarian Cancer ClinicalTrials.gov
    Fostamatinib 150 mg bid and Paclitaxel DRUG Phase PHASE1 Ovarian Cancer ClinicalTrials.gov
    Fostamatinib 100 mg bid and Paclitaxel DRUG Phase PHASE1 Ovarian Cancer ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Rigel Pharmaceuticals Inc
    • Ticker Symbol: RIGL

Search

News categories